TY  - JOUR
A1  - Hartrampf, Philipp E.
A1  - Heinrich, Marieke
A1  - Seitz, Anna Katharina
A1  - Brumberg, Joachim
A1  - Sokolakis, Ioannis
A1  - Kalogirou, Charis
A1  - Schirbel, Andreas
A1  - Kübler, Hubert
A1  - Buck, Andreas K.
A1  - Lapa, Constantin
A1  - Krebs, Markus
T1  - Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy — Do Different Software Solutions Deliver Comparable Results?
JF  - Journal of Clinical Medicine
N2  - (1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: \(^{68}\)Ga-PSMA PET/CT scans from n = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland–Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.
KW  - prostate-specific membrane antigen (PSMA)
KW  - metabolic tumour volume (MTV)
KW  - total lesion PSMA
KW  - biomarker
KW  - software
KW  - comparability
KW  - agreement
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-205893
SN  - 2077-0383
VL  - 9
IS  - 5
ER  - 
TY  - JOUR
A1  - Kotlyar, Mischa J.
A1  - Krebs, Markus
A1  - Solimando, Antonio Giovanni
A1  - Marquardt, André
A1  - Burger, Maximilian
A1  - Kübler, Hubert
A1  - Bargou, Ralf
A1  - Kneitz, Susanne
A1  - Otto, Wolfgang
A1  - Breyer, Johannes
A1  - Vergho, Daniel C.
A1  - Kneitz, Burkhard
A1  - Kalogirou, Charis
T1  - Critical evaluation of a microRNA-based risk classifier predicting cancer-specific survival in renal cell carcinoma with tumor thrombus of the inferior vena cava
JF  - Cancers
N2  - (1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava (ccRCC\(^{IVC}\)) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed a microRNA(miR)-based risk classifier — containing miR-21-5p, miR-126-3p and miR-221-3p expression — which significantly predicted the cancer-specific survival (CSS) of ccRCC\(^{IVC}\) patients. (2) Methods: Examining a single-center cohort of tumor tissue from n = 56 patients with ccRCC\(^{IVC}\), we measured the expression levels of miR-21, miR-126, and miR-221 using qRT-PCR. The prognostic impact of clinicopathological parameters and miR expression were investigated via single-variable and multivariable Cox regression. Referring to the previously established risk classifier, we performed Kaplan–Meier analyses for single miR expression levels and the combined risk classifier. Cut-off values and weights within the risk classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were significantly associated with lymphonodal status at the time of surgery, the development of metastasis during follow-up, and cancer-related death. In Kaplan–Meier analyses, miR-21 and miR-126 significantly impacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified ccRCC\(^{IVC}\) according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated the miR-based risk classifier within an independent ccRCC\(^{IVC}\) cohort.
KW  - kidney cancer
KW  - RCC
KW  - venous infiltration
KW  - biomarker
KW  - miR
KW  - risk stratification
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-311040
SN  - 2072-6694
VL  - 15
IS  - 7
ER  -